| Systemic Lupus Erythematosus |
ACTRN12618002060224: A Phase 1, Randomised, Double-Blind, placebo controlled, single and multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics of KZR-616 in healthy female subjects. |
|
|
| Not yet recruiting | 1 | 72 | | | Clinical Netwprk Services, Kezar Life Sciences | Chronic inflammatory conditions for example rheumatoid arthritis, Autoimmune disorders for example systemic lupus erythematosus | | | | |
300002: Proof-of-mechanism clinical trial of the TLR7 and TLR9 inhibitor, DV1179 |
|
|
| Recruiting | 1 | 0 | RoW | DV 1179 | Dynavax Technologies Corporation | systemic lupus erythematosus | | | | |
NCT05984251: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Participants |
|
|
| Completed | 1 | 48 | Europe | CCX168, Placebo | Amgen | Vasculitis, Systemic Lupus Erythematosus (SLE) | 09/10 | 04/11 | | |
| Completed | 1 | 29 | | 240 mg/m2 infusions weekly for 4 doses ;600 mg infusion weekly for 4 doses ;900 mg infusion weekly for 4 doses | Peking Union Medical College Hospital; Peking Union Medical College Hospital, SinoMab BioScience Limited | Systemic Lupus Erythematosus | | | | |
ChiCTR-OPC-15006322: Effective and safety evaluation of human umbilical cord derived mesenchymal stem cells (hU-MSCs)in systemic lupus erythematosus |
|
|
| Recruiting | 1 | 35 | | human umbilical cord derived mesenchymal stem cells (hU - MSCs) | Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing; Daping Hospital, The Third Military Medical University, self-financed | systemic lupus erythematosus | | | | |
ChiCTR1800020286: Clinical evaluation of the application of Langchuangjing granule in the treatment of systemic lupus erythematosus |
|
|
| Not yet recruiting | 1 | 60 | | Langchuangjing granule + Prednisone acetate tablets, hydroxychloroquine and other Western medicines for 12 weeks. ;Prednisone acetate tablets, hydroxychloroquine and other Western medicines for 12 weeks. | Nanjing University of Chinese Medicine Affiliated Hospital; Jiangsu Province Hospital of TCM, Nanjing University of Chinese Medicine Affiliated Hospital | Systemic Lupus Erythematosus | | | | |
ChiCTR1900022934: Study for the metabolic mechanism of Langchuangjing granule in the treatment of systemic lupus erythematosusin |
|
|
| Not yet recruiting | 1 | 60 | | Langchuangjing granule + Prednisone acetate tablets, Hydroxychloroquine ;Prednisone acetate tabletsăHydroxychloroquine ;nothing | Nanjing University of Chinese Medicine Affiliated Hospital; Jiangsu Province Hospital of TCM, Nanjing University of Chinese Medicine Affiliated Hospital | Systemic Lupus Erythematosus | | | | |
ChiCTR1900027717: Allogeneic hematopoietic stem cell transplantation for systemic lupus erythematosus Safety and efficacy Single-center open clinical trial |
|
|
| Recruiting | 1 | 30 | | Hematopoietic stem cell transplantation | DONGGUANGTAIXIN HOSPITAL; DONGGUANGTAIXIN HOSPITAL, Self-raising | Systemic lupus erythematosus | | | | |
NCT03656627: Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease |
|
|
| Terminated | 1 | 7 | US | Nivolumab | Alliance Foundation Trials, LLC., Bristol-Myers Squibb | Autoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis, Psoriasis, Giant Cell Arteritis, Polymyalgia Rheumatica, Systemic Lupus Erythematosus, Crohn Disease, Multiple Sclerosis, Ulcerative Colitis | 03/21 | 03/21 | | |
NCT06316791: Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases |
|
|
| Recruiting | 1 | 24 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | Lupus Erythematosus, Systemic | 12/24 | 12/25 | | |
NCT05030779: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 9 | RoW | Assigned Interventions CD19/BCMA CAR T-cells | Zhejiang University, Yake Biotechnology Ltd. | Systemic Lupus Erythematosus, Autoimmune Diseases | 03/22 | 09/22 | | |
ChiCTR2100045557: A single-dose, dose-escalation, randomized, double-blind, placebo-controlled clinical trial on the tolerability, safety, pharmacokinetics of GR1603 injection in healthy subjects |
|
|
| Recruiting | 1 | 28 | | 0.1mg/kg GR1603 injection ;0.3 mg/kg GR1603 injection ;1mg/kg GR1603 injection ;3mg/kg GR1603 injection ;0.3mg/kg placebo ;1mg/kg placebo ;3mg/kg placebo group | Clinical Trial Reseach Center of the Third Xiangya Hospital of Central South University; Genrix (Shanghai) Biopharmaceutical Co., Ltd, Self-funding | Systemic lupus erythematosus; Systemic sclerosis | | | | |
NCT04233164: Genomic Effects of Glucocorticoids in Patients With Systemic Lupus Erythematosus |
|
|
| Active, not recruiting | 1 | 47 | US | Solu-Medrol 1mg/kg, Solu-Medrol 250 mg | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Systemic Lupus Erythematous (SLE) | 05/22 | 03/25 | | |
NCT04976465: Treatment and Clinical Outcomes Among SLE Patients in Pregnancy |
|
|
| Recruiting | 1 | 200 | RoW | Anticoagulation, Without Anticoagulation | Qilu Hospital of Shandong University | Systemic Lupus Erythematosus, Pregnancy Related | 07/25 | 12/26 | | |
ACTRN12621001161819: A phase 1 clinical trial to evaluate the safety, pharmacokinetics/pharmacodynamics, and immunogenicity of single and multiple ascending subcutaneous doses of RS2102 in healthy adult subjects |
|
|
| Completed | 1 | 56 | | | Atridia Pty Ltd, Atridia Pty Ltd | Systemic lupus erythematosus | | | | |
ChiCTR2100054115: Safety, Tolerability, Pharmacokinetics and Immunogenicity of QX006N in Healthy Subjects: A Single-Center, Randomized, Double-Blind, Single-Dose ,Dose Escalation, Placebo-Controlled, Phase I Study |
|
|
| Not yet recruiting | 1 | 45 | | Single intravenous infusion of QX006N ;Conventional treatment | The First Hospital of Jilin University; the First Hospital of Jilin University, At sponsor's own expense | Systemic lupus erythematosus | | | | |
NCT05203692: A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects |
|
|
| Completed | 1 | 80 | US | DS-7011a, Placebo | Daiichi Sankyo, Inc. | Systemic Lupus Erythematosus | 01/23 | 03/23 | | |
NCT05203419: Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE) |
|
|
| Terminated | 1 | 8 | Europe | MHS552, Placebo | Novartis Pharmaceuticals | Lupus Erythematosus, Systemic | 06/23 | 06/23 | | |
ChiCTR2100048135: Effects of modified huangfeng decoction on long-Term prognosis of patients with systemic lupus erythematosus complicated with antiphospholipid antibody syndrome in childbearing age |
|
|
| Not yet recruiting | 1 | 100 | | Flavored Yellow Wind Soup ;Conservative treatment | Zhejiang Provincial Hospital of Traditional Chinese Medicine; Zhejiang Provincial Hospital of Traditional Chinese Medicine, self-funded | SLE | | | | |
NCT05247203: Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus |
|
|
| Completed | 1 | 92 | RoW | Telitacicept, RC18, standard therapy | RemeGen Co., Ltd. | Systemic Lupus Erythematosus | 10/23 | 11/23 | | |
NCT05846347: Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 15 | RoW | GC012F injection, CD19-BCMA CAR-T cells | Zhejiang University, Gracell Biotechnology Shanghai Co., Ltd. | CAR-T | 10/23 | 04/25 | | |
NCT06316076: Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases |
|
|
| Recruiting | 1 | 48 | RoW | CD19-CAR-DNT cells, Cyclophosphamide, Fludarabine | RenJi Hospital, Guangdong Ruishun Biotech Co., Ltd | Systemic Lupus Erythematosus, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Idiopathic Inflammatory Myopathies, Systemic Sclerosis | 06/24 | 06/26 | | |
EQUALISE, NCT04128579: Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis |
|
|
| Completed | 1 | 55 | Europe, US, RoW | Itolizumab [Bmab 600], Bmab600, Itolizumab | Equillium, Biocon Limited | Lupus Erythematosus, Lupus Nephritis | 11/23 | 01/24 | | |
|
|
|
|
|
NCT05858684: Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients |
|
|
| Recruiting | 1 | 18 | RoW | GC012F injection, CD19-BCMA CAR-T cells | RenJi Hospital, Gracell Biotechnology Shanghai Co., Ltd. | CAR-T Cell Therapy | 11/23 | 05/25 | | |
NCT06144710: SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 48 | RoW | SG301 SC Injection, SG301 SC Placebo | Hangzhou Sumgen Biotech Co., Ltd. | Systemic Lupus Erythematosus (SLE) | 05/25 | 10/25 | | |
NCT05048238: Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus |
|
|
| Completed | 1 | 7 | US | Tofacitinib, XELJANZ(R) XR | National Institute of Allergy and Infectious Diseases (NIAID) | Systemic Lupus Erythematosus, Cutaneous Lupus | 02/24 | 02/24 | | |
ChiCTR2200066345: A single-center, randomized, double-blind, placebo-controlled, single-dose escalation and multi-dose phase I clinical study investigating the safety, tolerability, pharmacokinetic/pharmacodynamic profile, and food effect of HE009 tablet administered orally in healthy adult subjects in China |
|
|
| Not yet recruiting | 1 | 92 | | Single oral administration (dose 1) ;Single oral administration (dose 2) ;Single oral administration (dose 3) ;Single oral administration (dose 4) ;Single oral administration (dose 5) ;Single oral administration (dose 6) ;Multiple oral administrations (dose 1) ;Multiple oral administrations (dose 2) ;Multiple oral administrations (dose 3) ;Multiple titration administration (dose 1) ;period 1: fasting state, period 2: fed state ;period 1: fed state, period 2: fasting state | The Second Hospital of Anhui Medical University; Nanchang Hongyi Pharmaceutical Co. Ltd., Nanchang Hongyi Pharmaceutical Co. Ltd. | Systemic Lupus Erythematosus | | | | |
NCT06150651: Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus. |
|
|
| Recruiting | 1 | 6 | RoW | CAR T-cell therapy | Chulalongkorn University, King Chulalongkorn Memorial Hospital, Health Systems Research Institute | SLE (Systemic Lupus) | 11/24 | 11/25 | | |
ChiCTR2200066574: A multicenter, randomized, double-blind, placebo-controlled, multiple-dose, stepped-up phase Ib clinical study of QX006N injection in adults with moderate to severe systemic lupus erythematosus |
|
|
| Not yet recruiting | 1 | 30 | | QX006N/placebo 150mg ;QX006N/placebo 300mg ;QX006N/placebo 600mg | The First Hospital of Jilin University ; the First Hospital of Jilin University, At sponsor's own expense | Systemic lupus erythematosus | | | | |
| Completed | 1 | 25 | Europe, RoW | M5049, Placebo | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus | 12/23 | 12/23 | | |
| Recruiting | 1 | 20 | US | Anifrolumab, Medi 546, Standard of Care, azathioprine, methotrexate, mycophenolate mofetil, corticosteroids, antimalarials | Oklahoma Medical Research Foundation, NYU Langone Health, Yale University, Piedmont Heart Institute, Inc., Atlanta, GA, Columbia University | Systemic Lupus Erythematosus (SLE) | 12/23 | 12/24 | | |
NCT05328557: A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers |
|
|
| Active, not recruiting | 1 | 32 | US | CUG252, Placebo | Cugene Inc. | Systemic Lupus Erythematosus | 12/23 | 12/23 | | |
NCT06222853: Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 19 | RoW | anti-CD19-CAR-T cells | The Children's Hospital of Zhejiang University School of Medicine, Chongqing Precision Biotech Co., Ltd | Systemic Lupus Erythematosus, CAR-T Cell Therapy | 12/26 | 12/26 | | |
NCT06188507: A First Time in Human Study to Evaluate the Safety and Tolerability of GSK3996401 Following Dosing With GSK4347859 in Healthy Participants |
|
|
| Not yet recruiting | 1 | 44 | Europe | GSK4347859, Placebo | GlaxoSmithKline | Systemic Lupus Erythematosus | 03/25 | 03/25 | | |
CARLYSE, NCT06333483: A Study of CD19 Targeted CAR T Cell Therapy in Patients With Severe, Refractory Systemic Lupus Erythematosus (SLE) |
|
|
| Recruiting | 1 | 12 | Europe | Obecabtagene autoleucel (obe-cel) | Autolus Limited | Systemic Lupus Erythematosus | 11/24 | 10/25 | | |
NCT04857151: Stress, Inflammation and Immune Response Pilot Study- Aim 3 |
|
|
| Completed | 1 | 3 | US | App based mindfulness program (ABMP) | University of Wisconsin, Madison | Systemic Lupus Erythematosus, Inflammation | 01/24 | 03/24 | | |
NCT06297408: Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus |
|
|
| Not yet recruiting | 1 | 24 | NA | Relma-cel, if necessary can add other anti-SLE treatment such as corticosteroids, immunosuppressants, biologics | Shanghai Ming Ju Biotechnology Co., Ltd. | Systemic Lupus Erythematosus | 05/25 | 05/26 | | |
CAR-AID, NCT06249438: A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy |
|
|
| Recruiting | 1 | 30 | RoW | CD20/BCMA-directed CAR-T cells, C-CAR168 | RenJi Hospital, AbelZeta Pharma Inc. | Systemic Lupus Erythematosus (SLE), Immune-Mediated Necrotizing Myopathy, Neuromyelitis Optica Spectrum Disorders, Multiple Sclerosis-Relapsing-Remitting | 03/27 | 03/40 | | |
NCT06308978: FT819 in Moderate to Severe Active Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 32 | US | FT819, Fludarabine, FLUDARA, Cyclophosphamide, CYTOXAN, Bendamustine | Fate Therapeutics | Systemic Lupus Erythematosus | 09/27 | 09/42 | | |
NCT06349343: CD19/BCMA HLA-independent TCR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus |
|
|
| Not yet recruiting | 1 | 20 | NA | CD19/BCMA Hi-TCR-T cell therapy | Wuhan Union Hospital, China | Systemic Lupus Erythematosus | 01/25 | 01/26 | | |
GLEAM, NCT06294236: Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases |
|
|
| Recruiting | 1 | 36 | US | SC291, Cyclophosphamide, Fludarabine | Sana Biotechnology | Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis | 12/27 | 03/28 | | |
NCT06400537: Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus |
|
|
| Not yet recruiting | 1 | 9 | NA | A-319 | Wuhan Union Hospital, China, ITabMed Co., Ltd. | Systemic Lupus Erythematosus | 05/25 | 05/26 | | |
NCT06417398: Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases |
|
|
| Not yet recruiting | 1 | 10 | NA | T cell injection targeting CD19 chimeric antigen receptor | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Sjogren's Syndrome, Rheumatoid Arthritis, Immune Thrombocytopenia, Primary Biliary Cholangitis | 12/24 | 05/25 | | |
NCT06340490: A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE) |
|
|
| Not yet recruiting | 1 | 24 | RoW | RJMty19 (CD19-CAR-DNT cells), Fludarabine, Cyclophosphamide | Guangdong Ruishun Biotech Co., Ltd, RenJi Hospital, Peking University People's Hospital, Changhai Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Systemic Lupus Erythematosus | 12/26 | 12/27 | | |
NCT06420154: The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases |
|
|
| Not yet recruiting | 1 | 9 | RoW | anti-CD19-CAR-T cells | First Affiliated Hospital of Wenzhou Medical University, Shanghai First Song Therapeutics Co., Ltd | Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy, ANCA Associated Vasculitis, Antiphospholipid Syndrome | 05/27 | 05/27 | | |
NCT06413511: A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Moderate to Severe Systemic Lupus Erythematosus |
|
|
| Not yet recruiting | 1 | 16 | US | Belantamab, GSK2857914 | GlaxoSmithKline | Systemic Lupus Erythematosus | 11/25 | 11/25 | | |
NCT05930314: CNCT19 Cell Injection for Refractory Systemic Lupus Erythematosus |
|
|
| Enrolling by invitation | 1 | 12 | RoW | CNCT19 cell injection | Peking Union Medical College Hospital | Refractory Systemic Lupus Erythematosus, Lupus Nephritis, Immune Thrombocytopenia | 05/24 | 05/25 | | |
NCT06421701: Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus |
|
|
| Not yet recruiting | 1 | 10 | RoW | anti-CD19 CAR-NK cells | Second Affiliated Hospital, School of Medicine, Zhejiang University | Systemic Lupus Erythematosus | 08/25 | 05/26 | | |
| Not yet recruiting | 1 | 18 | NA | LMY-920, BAFF CAR T | Luminary Therapeutics, Nationwide Children | Systemic Lupus Erythematosus | 10/25 | 04/26 | | |
NCT06468683: F01 in the Treatment of Moderate-to-severe Refractory Systemic Lupus Erythematosus |
|
|
| Not yet recruiting | 1 | 50 | RoW | After preconditioning with chemotherapy, F01 will be evaluated. | Shanghai Simnova Biotechnology Co.,Ltd. | Lupus Erythematosis | 01/27 | 12/27 | | |
NCT05866861: A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 40 | US | CUG252, Placebo | Cugene Inc. | Systemic Lupus Erythematosus, SLE (Systemic Lupus), Autoimmune | 07/24 | 07/24 | | |
NCT06465147: REACT-01: Reversing Autoimmunity Through Cell Therapy |
|
|
| Not yet recruiting | 1 | 12 | US | SCRI-CAR19v3 | Seattle Children's Hospital | Systemic Lupus Erythematosus | 07/28 | 07/41 | | |
NCT06462144: IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy |
|
|
| Not yet recruiting | 1 | 36 | RoW | IMPT-514 CART Cell Injection | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Systemic Lupus Erythematosus (SLE), ANCA Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathy (IIM) | 05/25 | 10/26 | | |
TQB3702-I-02, NCT06448273: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetic of TQB3702 Tablets in Healthy Adult Subjects |
|
|
| Not yet recruiting | 1 | 40 | RoW | TQB3702 tablets, TQB3702 placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Systemic Lupus Erythematosus | 10/24 | 10/24 | | |
NCT06238531: A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus |
|
|
| Not yet recruiting | 1 | 60 | US | Gusacitinib | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Systemic Lupus Erythematosus | 12/27 | 10/28 | | |
| Not yet recruiting | 1 | 12 | RoW | ATHENA CAR-T, ET-901, Fludarabine, Fludarabine Phosphate for Injection, Cyclophosphamide, Cyclophosphamide for Injection | EdiGene Inc., The First Affiliated Hospital of Henan University of Science and Technology, Changping Laboratory | Lupus Erythematosus, Systemic | 04/27 | 04/27 | | |
CALiPSO-1, NCT06255028: A Study of CNTY-101 in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE) |
|
|
| Not yet recruiting | 1 | 26 | US | CNTY-101, IL-2, Lymphodepleting Chemotherapy | Century Therapeutics, Inc. | Systemic Lupus Erythematosus | 08/28 | 08/28 | | |
NCT06010472: An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 12 | RoW | anti-CD19 CAR NK cells (KN5501) | Changhai Hospital, Rui Therapeutics Co., Ltd | Systemic Lupus Erythematosus (SLE) | 08/24 | 08/25 | | |
AIM-NIVO, NCT03816345: Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer |
|
|
| Recruiting | 1 | 300 | Canada, US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo | National Cancer Institute (NCI) | Autoimmune Disease, Crohn Disease, Dermatomyositis, Hematopoietic and Lymphoid Cell Neoplasm, Inflammatory Bowel Disease, Malignant Solid Neoplasm, Multiple Sclerosis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis | 08/24 | 08/24 | | |
NCT05155345: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus |
|
|
| Active, not recruiting | 1 | 50 | Europe, US, RoW | Mosunetuzumab, Tocilizumab | Hoffmann-La Roche | Systemic Lupus Erythematosus | 09/24 | 06/25 | | |
NCT05687526: A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 12 | RoW | Telitacicept 2.5 mg/kg, RC18 | RemeGen Co., Ltd. | Systemic Lupus Erythematosus | 10/24 | 12/24 | | |
NCT06335979: An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE). |
|
|
| Not yet recruiting | 1 | 54 | NA | PIT565 | Novartis Pharmaceuticals | Systemic Lupus Erythematosus, SLE | 11/27 | 11/27 | | |
NCT06429800: A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Lupus Nephritis |
|
|
| Not yet recruiting | 1 | 26 | NA | ATA3219 | Atara Biotherapeutics | Lupus Nephritis, Systemic Lupus Erythematosus | 10/27 | 04/29 | | |
NCT06411639: Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases |
|
|
| Not yet recruiting | 1 | 12 | NA | ianalumab, VAY736 | Novartis Pharmaceuticals | Sjogren Disease, Systemic Lupus Erythematosus | 12/25 | 06/28 | | |
ChiCTR2300073848: Clinical study of Qing Bai Chi Dan Decoction for maintenance treatment of systemic lupus erythematosus |
|
|
| Not yet recruiting | 1 | 60 | | According to the recommendations for mild to moderate systemic lupus erythematosus (SLE) proposed by the European League Against Rheumatism (EULAR) in 2019 and the 2020 Chinese Guideline for the Diagnosis and Treatment of Systemic Lupus Erythematosus, acetate prednisone tablets and hydroxychloroquine sulfate tablets should be used, along with orally administered Qing Bai Chi Dan Decoction placebo granules, for a treatment period of 24 weeks. ;Treatment with Qing Bai Chi Dan Decoction granules, acetate prednisolone tablets, and hydroxychloroquine sulfate tablets for 24 weeks. | Guang'anmen Hospital, China Academy of Chinese Medical Sciences; Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Institutional Scientific Research Fund of Guang'anmen Hospital, China Academy of Chinese Medical Sciences | Systemic Lupus Erythematosus | | | | |
NCT05411016: A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus |
|
|
| Recruiting | 1 | 116 | Japan | Placebo, KK4277 | Kyowa Kirin Co., Ltd. | Healthy Volunteers, Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE) | 12/24 | 03/25 | | |
ChiCTR2200059533: Construction and clinical medical model of SLE pregnant women's family planning and maternity care model based on APP platform |
|
|
| Not yet recruiting | 1 | 248 | | Use self-made SLE women planning pregnancy and maternity care APP ;None | The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, Youth incubation fund for nursing research of the First Hospital of Zhejiang University | Pregnancy complicated with systemic lupus erythematosus (SLE) | | | | |
NCT05765006: CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 24 | RoW | Relma-cel | Shanghai Ming Ju Biotechnology Co., Ltd. | Systemic Lupus Erythematosus | 12/24 | 12/25 | | |
NCT05917288: A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus |
|
|
| Not yet recruiting | 1 | 14 | NA | Belimumab, Standard of care | GlaxoSmithKline | Systemic Lupus Erythematosus | 01/25 | 01/25 | | |
NCT05474885: BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE) |
|
|
| Recruiting | 1 | 15 | RoW | BCMA-CD19 cCAR T cells | iCell Gene Therapeutics, iCAR Bio Therapeutics Ltd. China | Relapsed/Refractory, Systemic Lupus Erythematosus (SLE) | 04/25 | 04/25 | | |
NCT06041568: A Study of Imvotamab in Severe Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 18 | Europe, US, RoW | Imvotamab | IGM Biosciences, Inc. | Systemic Lupus Erythematosus, Lupus Erythematosus | 06/25 | 05/26 | | |
| Recruiting | 1 | 87 | Europe, US, RoW | GS-0272, Placebo | Gilead Sciences | Rheumatoid Arthritis | 06/25 | 06/25 | | |
NCT06013995: A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus |
|
|
| Recruiting | 1 | 60 | Europe, US, RoW | BMS-986326, Placebo for BMS-986326 | Bristol-Myers Squibb | Lupus | 11/25 | 11/25 | | |
NCT06056921: Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease |
|
|
| Recruiting | 1 | 24 | RoW | CD19 targeted CAR-T cells | Chongqing Precision Biotech Co., Ltd | SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma, Dermatomyositis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 12/25 | 08/26 | | |
NCT05835986: A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 70 | Europe, RoW | RO7507062, Tocilizumab, Actemra, RoActemra | Hoffmann-La Roche | Systemic Lupus Erythematosus | 11/27 | 11/27 | | |
NCT05869955: A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases |
|
|
| Recruiting | 1 | 129 | Europe, US | CC-97540, BMS-986353, Fludarabine, Cyclophosphamide | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, Bristol-Myers Squibb Services Unlimited Company | Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis | 11/27 | 11/27 | | |
